Antengene and XtalPi Announce AI-Driven R&D Collaboration
SHANGHAI and HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life-threatening diseases and XtalPi Inc, a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize...
BioWorld by Clarivate Identifies the Top Six Global Biopharmaceutical Stories and Trends of 2021
Advances in Alzheimer's, innovation in DNA vaccines, increased regulatory collaboration and the evolving impact of Artificial Intelligence, join Covid-19 as key stories and trends of 2021 LONDON, Dec. 16, 2021 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, has announced the six...
Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study
Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors LAUSANNE, Switzerland, Dec. 16, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1...
PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE’S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS
HEIDELBERG, Germany, and CAMBRIDGE, Mass., Dec. 16, 2021 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease (DED) associated with...
LifeTech and Medtronic Further Strategic Collaboration to Open New Chapter of Domestically-Made MRI-Conditional Pacemakers
SHENZHEN, China, Dec. 16, 2021 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 01302.HK) announced that it has extended its agreements with Medtronic to further the strategic collaboration on the "HeartTone™ domestic pacemaker project" and to start the collaboration on domestically-made MRI-conditional pacemakers. Together with MRI-conditional leads, these products will address growing MRI-related therapeutic needs in China. The agreements also include the extension of the partnership on the "HeartTone™ domestic pacemaker project" to 2028. Similar to its collaboration on the...
Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine
-- Takeda submits application for TAK-019/NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for NDA, to Japan's Ministry of Health, Labour and Welfare (MHLW) -- Interim data from Phase 1/2 trial in Japan demonstrate robust immune response and favorable tolerability with no serious adverse events GAITHERSBURG, Md., Dec. 16, 2021 /PRNewswire/ --...
The Clinician begins rollout of patient-reported outcome and experience measures for the Singapore public healthcare system
SINGAPORE, Dec. 16, 2021 /PRNewswire/ -- The Clinician, a global digital health leader, has partnered with Singapore's HealthTech agency, Integrated Health Information Systems (IHiS), to launch an electronic patient-reported outcome and experience measures (PROMs and PREMs) program across Singapore's public healthcare system. The purpose of the program is to measure and improve...
PRENETICS LAUNCHES CIRCLE HEALTHPOD AT HONG KONG INTERNATIONAL AIRPORT, PROVIDING TRAVELLERS WITH RAPID COVID-19 PCR QUALITY RESULTS IN LESS THAN 60 MINUTES
Results Available In the Form of Digital Health Passport, SMS and Email HealthPod Results Accepted by 13 Countries as Valid Pre-Departure COVID-19 Test: USA, Canada, UK, Spain, Germany, Italy, Netherlands, Sweden, Luxembourg, New Zealand, South Korea and more Circle HealthPod, with Technology Developed at University of Oxford, is a CE-IVD Marked Rapid Detection Health Monitoring System...
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy
TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g1 TARPEYO (developed under the project name NEFECON) is the first and only FDA-approved treatment specifically designed for this condition1,2 IgAN...
Menarini Silicon Biosystems announces new DEPArray™ PLUS application to identify mutations in FFPE tissue samples with low tumor cellularity
Tissue biopsies with tumor cell contents that are too low for conventional testing methods can now be rescued due to the ability of MSB's DEPArray technology* to successfully recover low numbers of tumor cells from these difficult samples. The new FFPE Rescue Application* will provide pathology labs with a validated workflow to...
